Pipeline Moves: Novartis completes ulcerative colitis trial, advancement prospects rise

Eisai is developing the oral drug for the treatment of pain, osteoarthritis (OA) knee pain, chronic low back pain, and DPNP. Phase I/II ophthalmology …
Source: back pain